1. Norway Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Photocure ASA

Photocure ASA

4.74
EUR
0.00
(0.00%)
0.27EPS
19.66P/E
142.08MMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.94
6.05
6.3
6.68
7
8.41
12.93
10.42
13.43
14.54
18.47
19.38
19.98
26.19
Basic EPS, GAAP
-2.78
-1.16
-1.69
1.64
-1.61
-1.7
1.46
-0.91
-1.15
-2.66
0.04
-0.12
-0.06
3.07
Free Cash Flow per Basic Share
-4.75
-0.33
-1.68
-0.14
-1.96
-1.22
0.9
0.57
0.75
-0.21
1.02
2.08
-0.38
1.34
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
12.62
11.24
9.8
11.69
10.12
8.1
9.58
19.03
18.64
17.07
17.81
18.51
18.2
22.8
Tangible Book Value per Share
12.62
11.24
9.24
10.46
8.57
7.07
9.04
7.49
7.85
6.93
8
9.09
8.73
9.06
Basic Weighted Avg Shares
21
21
21
22
22
22
22
25
27
27
27
27
27
26
Sales/Revenue/Turnover
84
129
135
144
151
182
282
256
361
393
501
525
533
679
Operating Margin (%)
-85.92
-4.37
-16.32
-11.04
-29.95
-13.06
15.18
-9.05
-1.62
-12.46
5.55
3.88
-0.14
16.67
Depreciation Expense
1
1
4
8
12
13
16
19
24
24
28
29
29
30
Net Income, GAAP
-59
-25
-36
35
-35
-37
32
-22
-31
-72
1
-3
-2
80
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
30.65
- -
- -
- -
89.95
139.8
- -
21.03
Profit Margin (%)
-70.5
-19.15
-26.85
24.58
-22.99
-20.22
11.31
-8.73
-8.57
-18.28
0.2
-0.64
-0.28
11.72
Working Capital
167
167
170
182
135
101
148
332
300
254
289
320
274
268
LT Debt
- -
- -
- -
- -
- -
- -
7
41
36
21
14
11
5
- -
Total Equity
269
240
210
252
218
176
209
508
503
463
483
502
484
607
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
14.81
- -
- -
- -
0.54
-1.56
- -
16.58
Return on Capital (%)
- -
- -
- -
- -
- -
- -
16.33
- -
- -
- -
0.71
-2.79
- -
21.1
Return on Common Equity (%)
-18.16
-9.7
-16.07
15.29
-14.76
-18.61
16.54
-6.25
-6.11
-14.89
0.21
-0.68
-0.31
14.76

Capital Structure

NOK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
5
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
1,883
1,562
1,606

Working Capital

NOK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
385
460
370
Cash, Cash Equivalents & STI
235
193
162
Accounts Receivable, Net
75
204
125
Inventories
44
39
55
Total Current Liabilities
111
96
101
Payables & Accruals
- -
- -
- -
ST Debt
5
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

NOK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.5%
-0.85%
-3.49%
Free Cash Flow
32.57%
-138.36%
-118.02%
Net Income, GAAP
-117.38%
-85.32%
-54.58%
Sales/Revenue/Turnover
16.14%
16.65%
1.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
118
145
120
142
525
2025
125
136
- -
137
533
2026
265
142
- -
- -
- -

Quarterly Earnings Per Share

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.29
0.45
-0.13
-0.21
-0.12
2025
-0.09
0.18
- -
-0.3
-0.06
2026
3.14
-0.03
- -
- -
- -

Quarterly Dividends Per Share

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Daniel Schneider
Full Time Employees
101
Sector
Health technology
Industry
Medical specialties
Address
Hoffsveien 4 Oslo OS Norway 0275
IPO Date
May 20, 2000
Website
ww.photocure.no
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Photocure ASA, a specialized pharmaceutical firm, concentrates its efforts on the research, development, manufacturing, sales, and global promotion of innovative pharmaceutical solutions. The company maintains a commercial presence across the Nordic regions, Germany, France, Austria, the United Kingdom, the Benelux countries, Italy, other European territories, Canada, and the United States. Its primary offering, Hexvix®/Cysview®, employs a unique photodynamic technology to enhance the visualization and management of bladder cancer during blue light cystoscopy, making cancer cells illuminate with a distinct pink glow. Additionally, Photocure has licensed Cevira®, a drug-device combination for the non-surgical management of human papillomavirus-induced pre-cervical lesions, to its partner Asieris Meditech Co., Ltd., which is currently undergoing regulatory review in China. The company distributes its core products to pharmaceutical wholesalers, pharmacies, and hospitals through both direct sales teams and strategic licensing collaborations. Established in 1993, Photocure ASA is headquartered in Oslo, Norway.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Photocure ASA (PHCUF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Photocure ASA (PHCUF) M&A Call Transcript

  • prnewswire.com

    Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics

  • seekingalpha.com

    Photocure ASA (PHCUF) Q1 2026 Earnings Call Transcript

  • prnewswire.com

    Photocure ASA: Results for the first quarter of 2026

  • prnewswire.com

    Photocure ASA: Update on Regulatory Classification for OAY Equipment

  • seekingalpha.com

    Photocure ASA (PHCUF) Q4 2025 Earnings Call Transcript

  • prnewswire.com

    Photocure ASA: Results for the fourth quarter of 2025

  • seekingalpha.com

    Photocure ASA (PHCUF) Q3 2025 Earnings Call Transcript

  • prnewswire.com

    Photocure ASA: Results for the third quarter of 2025

  • prnewswire.com

    Photocure ASA: Results for the second quarter of 2025

  • prnewswire.com

    Photocure ASA: Results for the first quarter of 2025

  • prnewswire.com

    Photocure ASA: Results for the fourth quarter of 2024

  • prnewswire.com

    Photocure ASA: Results for the third quarter of 2024